Volume 42, Issue 1, Pages (January 2005)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Diagnostics in hepatitis C: The end of response-guided therapy?
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Volume 59, Issue 1, Pages (July 2013)
Volume 65, Issue 1, Pages S82-S94 (October 2016)
Inflammasomes in liver diseases
Volume 61, Issue 4, Pages (October 2014)
Volume 50, Issue 4, Pages (April 2009)
MELD: the holy grail of organ allocation?
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?  Patrick Marcellin, E. Jenny Heathcote,
Volume 67, Issue 2, Pages (August 2017)
Reply to: “Serum HBV pgRNA as a clinical marker for cccDNA activity”
Hepatic CD141+IFNλ+ DC subset: One against all?
Volume 68, Issue 5, Pages (May 2018)
Chronic Hepatitis C Therapy: Changing the Rules of Duration
Volume 42, Issue 6, Pages (June 2005)
Julien Bissonnette, Dominique Valla, Pierre-Emmanuel Rautou 
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
Volume 51, Issue 6, Pages (December 2009)
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
NS5A inhibitors in the treatment of hepatitis C
Volume 69, Issue 4, Pages (October 2018)
Volume 65, Issue 1, Pages S82-S94 (October 2016)
Immigration and viral hepatitis
Diagnostics in hepatitis C: The end of response-guided therapy?
Virological tools to diagnose and monitor hepatitis C virus infection
Volume 66, Issue 1, Pages 1-4 (January 2017)
Ype P. de Jong, Charles M. Rice, Alexander Ploss  Journal of Hepatology 
Living donor liver transplantation: is the hype over?
David G. Bowen, Christopher M. Walker  Journal of Hepatology 
Volume 69, Issue 2, Pages (August 2018)
Volume 44, Pages S19-S24 (January 2006)
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
Volume 68, Issue 3, Pages (March 2018)
Chronic HCV infection and the clonality of intrahepatic T cells
Hepatitis C core protein – The “core” of immune deception?
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
Volume 70, Issue 1, Pages (January 2019)
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 62, Issue 3, Pages (March 2015)
Genomic risk of hepatitis C-related hepatocellular carcinoma
Darius Moradpour, Arash Grakoui, Michael P. Manns 
Autophagy in the liver Journal of Hepatology
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
EASL Clinical Practice Guidelines: Wilson’s disease
Volume 61, Issue 1, Pages S45-S57 (November 2014)
EASL Clinical Practice Guidelines on hepatitis E virus infection
Chronic Hepatitis C Therapy: Changing the Rules of Duration
Volume 50, Issue 4, Pages (April 2009)
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Volume 67, Issue 5, Pages (November 2017)
miR-122 – A key factor and therapeutic target in liver disease
Immigration and viral hepatitis
Clinical Practice Guidelines of the European Association for the study of the Liver – Advancing methodology but preserving practicability  Markus Cornberg,
HCV targeting of patients with cirrhosis
Pioglitazone as adjuvant therapy in chronic hepatitis C: Sequential rather than concomitant administration with pegylated interferon and ribavirin?  Lawrence.
Volume 63, Issue 1, Pages (July 2015)
Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection  Isabelle Chemin,
Volume 51, Issue 2, Pages (August 2009)
Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences  Zobair M. Younossi, Aybike Birerdinc,
Pathogenesis of cholestatic hepatitis C
Chimeric mouse model of hepatitis B virus infection
Volume 54, Issue 6, Pages (June 2011)
U.P. Neumann, M. Biermer, D. Eurich, P. Neuhaus, T. Berg 
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Volume 42, Issue 1, Pages 150-152 (January 2005) Contrary to HIV, hepatitis C virus is not associated with erythrocytes in vivo  Salima Sadallah, Markus Heim, Christoph Hess, Thomas Klimkait, Manuel Battegay, Jürg A. Schifferli  Journal of Hepatology  Volume 42, Issue 1, Pages 150-152 (January 2005) DOI: 10.1016/j.jhep.2004.07.027 Copyright © 2004 European Association for the Study of the Liver Terms and Conditions

Fig. 1 HCV-RNA in whole blood compared to erythrocytes pool in HCV chronically infected patients. The erythrocyte pool of HCV-RNA (IU/ml: International Units per milliliter) was compared to the total amount of HCV-RNA (IU/ml) recovered in whole blood (plasma+erythrocytes). Sixty-five of the samples had a negative erythrocyte HCV viral load i.e. below the threshold (bold line: 600IU/ml) of the quantitative PCR assay. The 57 positive samples had an erythrocyte HCV viral load distributed as follow: 46 below 1% of the total viral load—10 below 10% of the total viral load. Only one sample had a HCV RNA erythrocyte viral load just above 10%. Journal of Hepatology 2005 42, 150-152DOI: (10.1016/j.jhep.2004.07.027) Copyright © 2004 European Association for the Study of the Liver Terms and Conditions